The results were based on data from 22,714 participants in the trial and were published after 78 confirmed coronavirus cases were reported among the group.
In the first control point of data analyses, the vaccine demonstrated a 92% calculated efficacy rate while at the second point efficacy rate was 91.4%. The high efficacy rate of the vaccine above 90% was confirmed at each of the three control points of clinical trials.
According to the protocol of Phase III clinical trials of the Sputnik V vaccine, its interim efficacy is calculated at three statistically significant representative control points - upon reaching 20, 39 and 78 cases of novel coronavirus infection among volunteers both in the placebo group and in the group that received the vaccine, the Gamaleya Institute said.
The emergency authorisation to the frontline workers, however, did not, as would be usual, await the results of the gold-standard stage III trial.